The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.

And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to give rapid relief to depression symptoms, just approved ... s manufacturer, Johnson & Johnson, said ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy ... two oral antidepressants. The FDA in 2019 approved Spravato, a close ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.

Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...

Johnson & Johnson's Spravato has been approved ... the need for daily oral antidepressants," Martin added. The FDA approval of Spravato comes after a controlled study showed the nasal spray provided ...

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treatment the first and only ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.